Home/Pipeline/CDX-585

CDX-585

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Celldex Therapeutics

About Celldex Therapeutics

Celldex Therapeutics is a biopharmaceutical company committed to developing novel, targeted therapeutics for devastating diseases, with a primary focus in oncology and inflammatory conditions. Its strategy leverages proprietary antibody platforms to create precision medicines that engage the immune system. Key achievements include advancing barzolvolimab (CDX-0159) into late-stage clinical trials for chronic urticaria and generating compelling clinical data across its pipeline. The company's direction is centered on progressing its lead assets through pivotal studies while exploring their potential in additional indications.

View full company profile

Therapeutic Areas

Oncology Immunology Inflammatory Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active